NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Dec 13, 2024 05:16PM
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Dec 11, 2024 09:37PM
NewAmsterdam Pharma (NAMS) Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Dec 10, 2024 04:36PM
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Dec 10, 2024 04:34PM
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares Jun 9, 2023 04:01PM


Nov 23, 2022 08:03AM NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company
Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential